Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Jun 17, 2014 9:52am
151 Views
Post# 22666165

RE:RE:RE:$2.3 M private placement

RE:RE:RE:$2.3 M private placementHi GV.

I too was surprised by the low survey response rate. I can't explain it. It is very quick to complete and totally confidential. I am a shareholder of RVX and Zenith and I am not associated with the company. Perhaps I should leave it open for a month. It is still open at https://www.surveymonkey.com/s/79NWLRH

Even though there were only 24 responses I do believe the data are reflective of the situation.

Here is bit more in depth interpretation of what the numbers mean.
The measurements were done using 10 point scales (1 to 10 with the 10 scores indicating extremely high satisfaction and 1 meaning extremely low satisfaction).
In the following I've used the average scores.
  1. Satisfaction with communications scored a very low average of 2.4 out of 10.
  2. This, in turn, resulted in a very low perception of the rate of progress of, again, 2.4 out of 10.
  3. Both of these factors, the perception of poor communications and the perception of lack of progress drag down the perception of management's ability to take rvx-208 to the next stage to a mid level range of 4.6 out of 10.
  4. Keep in mind that the management confidence score is at mid level (even though communications and progress rate much lower) but it could be much higher. How? By developing effective and progressive communications.
  5. These factors result in a grossly undervalued share price and this has many dissadvantages both for existing shareholders and the ability to raise capital.

So from my perspective the low level of and poor commincations is not a trivial matter. It is hurting all of us very significantly.

Now, I fully admitt that if Don is currently involved in negotiating the next big deal (CVR) then the communications don't matter quite as much but communications is still very important. LET'S HOPE DON IS DEEP INTO THE NEGOTIATIONS AND ABOUT TO CLOSE THE DEAL.

I remain hopeful. I believe rvx-208 will be proven to have tremendous potential. The quality of the board and advisory boards is very high. These people would not stick around if the product was a dud. NGNs involvement is very significant.

On the Zenith side we all know epigenetics is hot and unlimited in potential but here again the communications is ineffective. Zenith should be building the market in anticipation of various IPO spin outs.

IMHO    GLTA
Cheers
Toinv

Bullboard Posts